Report Category

Pharmaceutical Market Research Reports

In-depth market intelligence covering drug development, CDMO outsourcing, API manufacturing, biosimilars, oncology, cell & gene therapy, clinical trials, and specialty pharma — with 10-year forecasts, 15–25 KOL interviews per report, and competitive landscape analysis.

340+
Reports
10yr
Forecasts
15–25
KOL Interviews

Pharmaceutical Industry Market Intelligence

The global pharmaceutical market continues to evolve rapidly, driven by the acceleration of biologics and biosimilar development, the expansion of CDMO outsourcing models, advances in cell and gene therapy manufacturing, and the growing demand for complex drug delivery systems. InsightAce Analytic's pharmaceutical report library covers the full value chain — from active pharmaceutical ingredient sourcing and continuous manufacturing to clinical trial logistics and post-market commercialization.

CDMO & Contract ManufacturingOutsourcing models, capacity analysis, competitive positioning
API & Drug SubstanceSupply chain, HPAPI, peptide APIs, oligonucleotides
Oncology & Immuno-OncologyADCs, bispecifics, CAR-T, radiopharmaceuticals
Drug Delivery SystemsLNP platforms, nasal, transdermal, implantable devices
Biosimilars & BiologicsPatent cliffs, pipeline analysis, market penetration
Cell & Gene TherapyManufacturing, logistics, vein-to-vein supply chain
Clinical Trials & CRODecentralized trials, site management, real-world evidence
Rare Diseases & Orphan DrugsRegulatory pathways, pricing, competitive dynamics
CNS & NeurologyNeurodegeneration, psychiatric, digital therapeutics

Non-Sterile Outsourcing Market, Share & Trends Analysis Report, By Dosage form (Oral, Ear & Eye, Nasal, Topical, Parenteral), By Application (Human Medication, Nutraceuticals, Cosmetics, Medical Devices, Veterinary Health), By Region, and Segment Forecasts, 2024-2031

The Non-Sterile Outsourcing Market Size is valued at USD 7.50 Bn in 2023 and is predicted to reach USD 10.81 Bn by the year 2031 at an 4.8% CAGR during the forecast period for 2024-2031. A compounded medication product can be either non-sterile or sterile and contains one or more active ingredients. While it is possible to manufacture compounded sterile products internally, an alternative is to contract with a 503B outsourcing facility outside...

ID: 2740 180 Pages September 2024

GMP Biologics Market, Share & Trends Analysis Report, By Type (Monoclonal Antibodies, Polyclonal Antibody), By Application (Hospitals, Clinics, Others), By Region, and Segment Forecasts, 2024-2031

The GMP Biologics Market Size is valued at USD 52.3 Bn in 2023 and is predicted to reach USD 153.9 Bn by the year 2031 at an 14.6% CAGR during the forecast period for 2024-2031. The term "Good Manufacturing Practice" (GMP) Biologics describes the manufacture of biologic pharmaceuticals by strict legal requirements intended to guarantee the effectiveness, safety, and quality of the final product. The World Health Organization (WHO) and other or...

ID: 2715 180 Pages August 2024

Medical Device Package Validation Market Size, Share & Trends Analysis Report, By Testing Type (Physical Testing, Microbial Testing, Chemical Testing, and Visual Testing), By Device Class (Class I Devices, Class II Devices, and Class III Devices)), By Nature, By Sales Channel, By Region, Forecasts, 2024-2031

The Medical Device Package Validation Market Size is predicted to grow at a 8.61% CAGR during the forecast period for 2024-2031. The whole process of packaging validation is the identification and management of materials and production factors influencing the capacity of a packaged product to satisfy acceptance criteria. Validation's outcomes provide various advantages. Process control and assurance are attained to fulfil the device package cr...

ID: 2701 180 Pages August 2024

Hematological Malignancies Drugs Market Size, Share & Trends Analysis Report By Drugs (Monoclonal Antibodies, CAR-T Cell Therapy), By Pipeline Products, By Indication (Leukemia, Lymphoma), By Region, And Segment Forecasts, 2024-2031

The Hematological Malignancies Drugs Market Size is estimated to grow at a CAGR of 14.2% during the forecast period for 2024-2031.  Hematologic malignancies are cancers that most often start in the bone marrow or the immune system cells. Lymphom, leukemia, and multiple myeloma are the three most common blood malignancies. The development of innovative agents has contributed to improved outcomes for cancer patients in recent years, re...

ID: 1211 180 Pages August 2024

Antibody Hit Generation and Screening Market Size, Share & Trends Analysis Distribution By Application (Cancer, Autoimmune Diseases, Infectious Diseases), Technologies (Hit Generation, Phage Display, Yeast Display, Ribosome Display, B-Cell Hybridoma Technology, Computational Tools, Screening), Antibody Type And Segment Forecasts, 2024-2031

The Antibody Hit Generation and Screening Market Size is predicted to grow at an 9.78% CAGR during the forecast period for 2024-2031. Antibody hit generation and screening is a vital step in developing therapeutic antibodies, focusing on identifying and selecting candidates that bind to a target antigen with high affinity and specificity. This process leverages various technologies like hybridoma technology, phage display, yeast display, ribos...

ID: 2667 180 Pages August 2024

Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market Size, Share & Trends Analysis Report By Cloud (Private, Public, and Hybrid), Service (Infrastructure as a Service (IaaS), Platform as a Service (PaaS), and Software as a Service (SaaS)), End-Users, Region, And Segment Forecasts, 2024-2031

The Cloud-based Solutions for Drug Discovery, Development and Manufacturing Market Size is valued at 6.72 billion in 2023 and is predicted to reach 17.32 Million by the year 2031 at a 12.62% CAGR during the forecast period for 2024-2031. Key Industry Insights & Findings from the Report: Increasing adoption of advanced technologies, manual error reductions in drug development processes due to cloud-based applications, fast implem...

ID: 1026 180 Pages August 2024

Ovarian Cancer Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Surgery), Region And Segment Forecasts, 2024-2031

The Ovarian Cancer Market is expected to grow at a 10.5% CAGR during the forecast period for 2024-2031.  Ovarian cancer rank fifth in cancer deaths among women and accounting for more deaths than any other cancer of the female reproductive system. Previously it believed that cancer begin only in the ovaries, but recent evidence suggests that many ovarian cancer may start in the fallopian tubes. Factors can increase risk of cancer include ol...

ID: 1067 180 Pages August 2024

Breast Cancer Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Surgery), Region And Segment Forecasts, 2024-2031

The Breast Cancer Market is expected to grow at an 8.8% CAGR during the forecast period for 2024-2031.  Breast cancer start when cells in the breast begin to grow out of control. These cells form tumour that can often see on an x-ray. Breast cancer is the most common cancer among women, after skin cancer and second leading cause of cancer death in women after lung cancer. Breast cancer is broadly classified into two include non-invasive and...

ID: 1069 180 Pages August 2024

Clinical Trial Services Market Size, Share & Trends Analysis Report By Service (Clinical Trial Site Management, Patient Recruitment Management, (Patient recruitment & registry services, Patient retention, Others), Data Management, Administrative staff, IRB, Others), By Phase, (Phase I, Phase II, Phase III, Phase IV), By Sponsor, By Region, Forecasts, 2024-2031

The Global Clinical Trial Services Market size is valued at USD 22.58 billion in 2023 and is predicted to reach USD 42.86 billion by the year 2031 at an 8.44% CAGR during the forecast period for 2024-2031. The services used by biopharmaceutical or pharmaceutical companies to conduct clinical trial either for the approval of a new drug or biologic or for the entry of new generic or biosimilar to the market is ...

ID: 1071 180 Pages August 2024

3D Printed Medical Sensor and Biosensor Market Size, Share & Trends Analysis Report By Technology (Magnetic Levitation Technology, Inkjet-based Technology, Syringe-based Technology, Laser-based Technology, Others), By Material, By Region, And By Segment Forecasts, 2024-2031

The 3D Printed Medical Sensor and Biosensor Market is expected to grow at a 12% CAGR during the forecast period for 2024-2031.  3D printed medical sensors and biosensors, which are made utilizing cutting-edge production techniques, are used to create a variety of medical testing and tracking products. The urgent need for unique production technologies in the medical industry to boost output and reduce costs will help the overall company's...

ID: 1321 180 Pages August 2024

Key Pharmaceutical Sub-Segments We Cover

CDMO & Contract Manufacturing

The pharmaceutical CDMO market is expanding rapidly as drug developers increasingly outsource manufacturing to reduce capital expenditure and accelerate time-to-market. Our CDMO reports cover small molecule contract manufacturing, biologics CDMO, fill-finish services, and continuous manufacturing outsourcing with competitive landscape analysis of leading CDMOs worldwide.

API & Drug Substance Manufacturing

Active pharmaceutical ingredient sourcing and manufacturing is a critical strategic decision for pharma companies. Our API reports analyze supply chain dynamics, pricing trends, geographic manufacturing shifts, and the growing demand for high-potency APIs, peptide APIs, and oligonucleotide synthesis.

Drug Delivery Systems

Innovation in drug delivery — from nasal and transdermal systems to lipid nanoparticle platforms and controlled-release formulations — is reshaping how therapeutics reach patients. We cover the full spectrum of delivery technologies including inhalation devices, implantable systems, and targeted nanoparticle carriers.

Oncology & Immuno-Oncology

Oncology remains the largest therapeutic area by R&D investment. Our reports cover bispecific antibodies, antibody-drug conjugates, checkpoint inhibitors, CAR-T therapies, radiopharmaceuticals, and companion diagnostics with pipeline analysis and competitive positioning.

Biosimilars & Biologics

The biosimilar market is driven by patent cliffs of blockbuster biologics and increasing regulatory clarity. We analyze biosimilar development pipelines, interchangeability trends, market penetration dynamics, and the competitive strategies of both originator and biosimilar manufacturers.

Why Choose InsightAce for Pharmaceutical Market Intelligence?

  • Original primary research — 15–25 KOL interviews per report with pharma executives, CDMO leaders, formulators, and regulatory experts
  • 10-year market forecasts — analyst-built models with top-down and bottom-up triangulation, covering 2026–2035
  • Competitive landscape — detailed profiling of 15–25 companies per report including revenue analysis, pipeline mapping, and strategic positioning
  • Segmentation depth — by type, application, technology, formulation, route of administration, end-user, and region
  • Post-purchase support — dedicated analyst hours for follow-up questions, custom data tables, and presentation-ready slides

Frequently Asked Questions

How many pharmaceutical market research reports does InsightAce publish?

InsightAce Analytic has published 340+ pharmaceutical market research reports covering drug development, CDMO outsourcing, API manufacturing, biosimilars, clinical trials, and specialty pharma with 10-year forecasts.

What pharmaceutical sub-segments does InsightAce cover?

We cover CDMO & contract manufacturing, API & drug substance, drug delivery systems, oncology & immuno-oncology, biosimilars & biologics, cell & gene therapy, rare diseases & orphan drugs, CNS & neurology, and clinical trials & CRO markets.

What is included in InsightAce pharmaceutical reports?

Each report includes 10-year market size forecasts, competitive landscape with 15-25 company profiles, segmentation by type, application, and region, 15-25 KOL interviews, and post-purchase analyst support.

Can I customize a pharmaceutical report?

Yes. Every report purchase includes free 10% customization. You can add countries, extend the forecast period, add company profiles, or request specific segmentation cuts.

How do I request a sample pharmaceutical report?

Click "Request Sample" on any report card to receive an executive summary, table of contents, and sample data tables delivered to your email.